Healthcare Industry News: bone graft
News Release - December 3, 2008
MEDTRONIC STATEMENT(HSMN NewsFeed) - In response to The Wall Street Journal’s December 3, 2008 article, Medtronic issued the following statement:
Upon review of the known information, Medtronic, Inc. (NYSE: MDT) said its technical consultant in this case denies that he recommended the off-label use of the company’s InFuse® bone graft product. The physician who performed the procedure has also said, “The decision to use InFuse during surgery was a clinical decision based on my personal experience with the product and evidence presented at our professional medical society meetings, and had nothing to do with the Medtronic technical expert.”
Given the complexity of the products and procedures involved, Medtronic technical support is routinely made available to surgeons. Medtronic does not promote off label use of products, and physicians decide how medical products are ultimately used to the benefit of patients. The medical community understands that technical field representatives play a critical role in the operating room. In fact, most surgeons who use medical devices in their procedures require that a technical field representative be present during the procedure, because they understand their special product expertise enhances patient safety. Additionally, prominent medical societies, such as the American College of Surgeons, have policy statements describing the important role of industry representatives in the operating room. Medtronic’s technical representatives are in the operating room at surgeons’ request.
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 25, 2008. Actual results may differ materially from anticipated results.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsMedtronic Expands ENT Portfolio with FDA Clearance of NIM Vital(TM) Next Generation Intraoperative Nerve Monitoring System and Acquisiton of Ai Biomed Corp.
Medtronic Launches Head-to-Head TAVR Study Comparing the Evolut(TM) TAVR Platform Against the Edwards SAPIEN Valve in Small Annulus Patients
Medtronic Announces First Patient Implanted in ELITE Study of InterStim(TM) Micro